Pharmafile Logo
Pharmafocus logo
Advanced Search

Astellas to commercialise new kidney cancer drug in Europe

February 21, 2011
Sales and Marketing Astellas, Aveo Pharmaceuticals, Cancer, Kidney cancer, rcc, renal cell carcinoma, tivozanib

Astellas and Aveo Pharmaceuticals are to commercialise Aveo’s investigational kidney cancer drug tivozanib in Europe and the US. Aveo is …

News

J&J hit by another string of product recalls

February 21, 2011
Manufacturing and Production J&J, JJ, Johnson & Johnson, Simponi, golimumab, manufacturing compliance, pharma recalls

There seems to be no end to the quality troubles plaguing Johnson & Johnson, with several more recalls to report, …

News
Merck KGaA

Merck KGaA sales soar

February 21, 2011
Sales and Marketing 2010 pharma results, Cladribine, Merck KGaA, Merck Serono, Movectro

Merck KGaA’s sales jumped last year by nearly a fifth as recent acquisitions and strong growth on core products set …

News

Matt de Gruchy to lead Ogilvy Healthworld UK

February 18, 2011
Medical Communications Matt de Gruchy, Ogilvy Healthworld UK, appointment, medical communications

Comms agency Ogilvy Healthworld UK has appointed Matt de Gruchy as chief executive. Matt is a 14 year veteran of …

Appointment
Blog footer

Digital Pharma: Merck Serono sets up MS social network

February 18, 2011
Medical Communications Digital Pharma blog, MS, Merck Serono, Movectro, Rebif, multiple sclerosis, social networking

Merck Serono has set up an international social network for multiple sclerosis patients, saying today’s pharma companies should go beyond …

News
Merck Serono headquarters

Merck Serono halts Movectro European licence application

February 18, 2011
Medical Communications, Sales and Marketing Cladribine, MS, Merck KGaA, Merck Serono, Movectro, fingolimod, gilenya, multiple sclerosis

Merck Serono has withdrawn its European licence application for multiple sclerosis drug Movectro. Movectro (cladribine) is a new oral treatment …

News

Value-based pricing will not harm industry, says NICE chief

February 18, 2011
Sales and Marketing Health Select Committee, Health and Social Care Bill, NHS reform, NICE, Sir Andrew Dillon, value-based pricing

NICE’s chief executive Sir Andrew Dillon says he believes plans to introduce value-based pricing of medicines will not have a …

News

AZ accepts $92.5m to settle respiratory dispute

February 18, 2011
Sales and Marketing AZ, AstraZeneca, MedImmune, PDL BioPharma, Synagis, patent dispute, respiratory

AstraZeneca’s MedImmune subsidiary is to receive $92.5 million as part of a legal settlement involving its respiratory drug Synagis. PDL …

News

Trial failures threaten UK biotech

February 18, 2011
Research and Development AML, AS1411, AS1413, Antisoma, Juvista, Renovo, UK biotech, acute myeloid leukaemia, anti-scarring, biotech

A number of late stage failures from British biotech firms have left a looming question mark over the future of …

News

Bennett appointed chairman of Monitor

February 18, 2011
Sales and Marketing Monitor, NHS

Monitor, the body which will take on a powerful new role in regulating competition in the NHS, has a new …

News

Vidaza patient access scheme sways NICE

February 17, 2011
Sales and Marketing Celgene, NICE, Vidaza

Celgene’s Vidaza has been recommended by NICE in final draft guidance issued today. Vidaza (azacitidine) is recommended as a treatment …

News

e-Therapeutics success in £17 million financing

February 17, 2011
Research and Development, Sales and Marketing ETS2101, Invesco, e-Therapeutics

UK drug discovery and development company e-Therapeutics has successfully raised £17.6 million through a new share issue. The deal attracted …

News
Tyverb

Pharma industry R&D pipelines

February 16, 2011
Research and Development pipeline, pipelines

 New medicines which advance the treatment of diseases are the lifeblood of the pharmaceutical industry, and billions are invested by …

Feature
Lilly HQ

Lilly hails progress of new R&D approaches

February 16, 2011
Research and Development, Sales and Marketing Chorus, Mirror Portfolio, R&D, lilly

Lilly says two of its experimental approaches to re-designing R&D are beginning to pay off.Like all of its peers, the …

Feature

Companies join forces to promote AF awareness

February 16, 2011
Medical Communications, Sales and Marketing AF, Multaq, Pradaxa, apixaban, atrial fibrillation

Boehringer Ingelheim and Sanofi-Aventis are to co-sponsor the World Heart Federation’s global atrial fibrillation (AF) education campaign. AF AWARE was …

News

Sanofi seals Genzyme deal for $20 billion

February 16, 2011
Research and Development, Sales and Marketing Genzyme, Sanofi

Sanofi-Aventis has finally agreed a deal to buy Genzyme for $20.1 billion after eight months of wrangling with the US …

News

Sefton takes over at Ketchum Pleon healthcare

February 16, 2011
Medical Communications Ketchum Pleon, PR, appointment, medical communications, recruitment

Ketchum Pleon, the leading communications consultancy in the UK and Europe, has announced today that Amanda Sefton has been named …

News
Obama

Obama’s generics plan criticised

February 15, 2011
Sales and Marketing FDA, Obama, PhRMA, generics, reform

US pharma says new plans to end ‘pay-for-delay’ generics deals and shave five years from biologics exclusivity will threaten innovation …

News
Sartoris

Sartorius reaps rewards from Asian boom

February 15, 2011
Manufacturing and Production

German lab and processing equipment group Sartorius reported a bumper year in 2010, with revenues up nearly 10% on the …

News

Merck repels jaw injury claim

February 15, 2011
Sales and Marketing Fosamax, Merck, US, lawsuit

A New Jersey state court jury has found in favour of Merck & Co in the company’s ongoing legal battle …

News
The Gateway to Local Adoption Series

Latest content

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026